WO2019027299A3 - 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물 - Google Patents

간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물 Download PDF

Info

Publication number
WO2019027299A3
WO2019027299A3 PCT/KR2018/008903 KR2018008903W WO2019027299A3 WO 2019027299 A3 WO2019027299 A3 WO 2019027299A3 KR 2018008903 W KR2018008903 W KR 2018008903W WO 2019027299 A3 WO2019027299 A3 WO 2019027299A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
preventing
active ingredient
vascular disorders
stem cell
Prior art date
Application number
PCT/KR2018/008903
Other languages
English (en)
French (fr)
Other versions
WO2019027299A2 (ko
Inventor
박훈준
박봉우
정수현
이순민
김혜연
조동우
장진아
김석원
산스크리타 다스
Original Assignee
주식회사 에스엘바이젠
가톨릭대학교 산학협력단
포항공과대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 에스엘바이젠, 가톨릭대학교 산학협력단, 포항공과대학교 산학협력단 filed Critical 주식회사 에스엘바이젠
Publication of WO2019027299A2 publication Critical patent/WO2019027299A2/ko
Publication of WO2019027299A3 publication Critical patent/WO2019027299A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Abstract

본 발명은 간세포성장인자 (HGF) 단백질을 발현하는 중간엽줄기세포를 유 효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명의 HGF 단백질을 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관 계 질환 예방 또는 치료용 약학 조성물은 HGF를 발현하여 혈관신생을 유도함으로 써 모세혈관의 형성을 촉진시키고 심기능을 향상시킨다. 따라서, 본 발명의 약학 조성물은 혈관계 질환, 특히 심혈관계 질환의 예방 또는 치료용 약학 조성물로 유용하게 활용될 수 있다.
PCT/KR2018/008903 2017-08-04 2018-08-06 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물 WO2019027299A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170099112 2017-08-04
KR10-2017-0099112 2017-08-04

Publications (2)

Publication Number Publication Date
WO2019027299A2 WO2019027299A2 (ko) 2019-02-07
WO2019027299A3 true WO2019027299A3 (ko) 2019-04-25

Family

ID=65233029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/008903 WO2019027299A2 (ko) 2017-08-04 2018-08-06 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물

Country Status (2)

Country Link
KR (1) KR20190015153A (ko)
WO (1) WO2019027299A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210030806A1 (en) * 2019-03-28 2021-02-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Intraperitoneal injection of human placenta stem cells protect the brain from stroke injury via exosome/microparticle formation and ace2 maintenance of brain perfusion
JP2022542247A (ja) * 2019-07-24 2022-09-30 エスエルバイジェン インコ―ポレイテッド 不死化幹細胞株の製造方法およびその用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547856A (en) * 1992-05-18 1996-08-20 Genentech, Inc. Hepatocyte growth factor variants
KR20010033064A (ko) * 1997-12-12 2001-04-25 스티븐 에이. 서윈. 엠.디. 높은 역가를 갖는 안전한 재조합 렌티바이러스 벡터를생성시키는 방법 및 수단
KR20150009528A (ko) * 2012-03-28 2015-01-26 가부시키가이샤 쿠오리맨 불사화 줄기세포 및 그 생산물을 유효 성분으로 하는 의약 조성물 및 의약 제제
KR20170093084A (ko) * 2016-02-04 2017-08-14 주식회사 에스엘바이젠 간세포성장인자를 발현하는 중간엽줄기세포 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547856A (en) * 1992-05-18 1996-08-20 Genentech, Inc. Hepatocyte growth factor variants
KR20010033064A (ko) * 1997-12-12 2001-04-25 스티븐 에이. 서윈. 엠.디. 높은 역가를 갖는 안전한 재조합 렌티바이러스 벡터를생성시키는 방법 및 수단
KR20150009528A (ko) * 2012-03-28 2015-01-26 가부시키가이샤 쿠오리맨 불사화 줄기세포 및 그 생산물을 유효 성분으로 하는 의약 조성물 및 의약 제제
KR20170093084A (ko) * 2016-02-04 2017-08-14 주식회사 에스엘바이젠 간세포성장인자를 발현하는 중간엽줄기세포 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WANG, QIANG-LI ET AL.: "Mesenchymal Stem Cell -loaded Cardiac Patch Promotes Epicardial Activation and Repair of the Infarcted Myocardium", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 21, no. 9, 28 February 2017 (2017-02-28), pages 1751 - 1766, XP055594993 *
ZHU, XIAOYU ET AL.: "Establishment of a Lentiviral Vector Encoding Human HGF and the Infection of Human ADSCs", BIOMED RESEARCH INTERNATIONAL, vol. 2013, 2013, pages 1 - 8, XP055594990 *

Also Published As

Publication number Publication date
KR20190015153A (ko) 2019-02-13
WO2019027299A2 (ko) 2019-02-07

Similar Documents

Publication Publication Date Title
EP3735978A4 (en) COMPOSITION FOR THE IMPROVEMENT, PREVENTION OR TREATMENT OF SKIN DISEASES WITH INDUCED PLURIPOTENT, STEM CELL-DERIVED MESENCHYMAL STEM CELLS AND EXOSOME DERIVED FROM THEM
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2020003351A (es) Metodos, composiciones y elementos implantables que comprenden celulas activas.
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
EP4272731A3 (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
MY183637A (en) Compounds and uses thereof for the modulation of hemoglobin
EP4257152A3 (en) Apelin polypeptides
MX2021013581A (es) Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos.
EP3659585A4 (en) COMPOSITION FOR ADMINISTERING PHYSIOLOGICALLY ACTIVE SUBSTANCES INTO A BLOOD VESSEL
MY191087A (en) Compounds and uses thereof for the modulation of hemoglobin
PH12018500690A1 (en) Novel insulin analogs and use thereof
AU2018269275A1 (en) Five- and six-membered aza-aromatic compound, preparation method therefor, pharmaceutical composition, and application
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
MX2020000713A (es) Metodos de aferesis y sus usos.
MX2019005821A (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas.
WO2019027299A3 (ko) 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물
WO2019004792A3 (ko) 인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도
EP3476395A4 (en) COMPOSITION FOR INJECTION THAT CAN BE USED FOR THE TREATMENT OF CARDIAC DISEASES AND CONTAINING FIBROBLASTS, AND METHOD FOR PRODUCING FIBROBLASTS FOR THERAPEUTIC USE
MX2019014867A (es) Metodo para tratar un efecto secundario de la inmunoterapia.
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
MX2021008941A (es) Moduladores gpr35.
WO2016205397A3 (en) Target-specific delivery of therapeutic agents
MX2019012738A (es) Peptido para inducir la regeneracion de tejido, y uso del mismo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18840632

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18840632

Country of ref document: EP

Kind code of ref document: A2